Being the third¹ liquid biopsy test for Biocartis, the newly launched assay, Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
A revolution in liquid biopsy cancer research.
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study  by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing:
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Assay (Research Use Only) to their core oncology menu, that now covers most known and used oncology biomarkers.
Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.
The test selection for the Orion GenRead system will expand soon with the launch of the Orion GenRead Campylobacter test.
Orion Diagnostica’s Orion GenRead is a flexible benchtop solution including a small instrument and ready to use kits. It is intended for rapid detection of pathogens, offering a fast and accurate alternative for nucleic acid testing in various laboratory settings.